Clinical Trial Update: Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC [Phase 3]

View source ↗

Summary

Phase 3 trial update noting the addition of a PD-1 inhibitor to neoadjuvant and adjuvant therapy for Nasopharyngeal Carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• PD-1 inhibitor

Snippet

Sponsor: Jiangxi Provincial Cancer Hospital | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: UNKNOWN